ArticleAsian Pacific journal of cancer prevention : APJCP2025
The Janus kinase 2 (JAK2) Mutation Burden is Related to Hematological Outcomes in Thai Patients with Myeloproliferative Neoplasms.
Article in Asian Pacific journal of cancer prevention : APJCP, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundAt present, data on the Janus kinase 2 (JAK2) mutation allele burden in Thai patients are limited. The aim of this study was to determine the prevalence of JAK2 V617F mutations and their association with the clinicohematological parameters of Thai patients with myeloproliferative neoplasms (MPNs).
methodsJAK2 V617F mutation status and allele burden were analyzed in 394 MPN patients using TaqMan polymerase chain reaction (PCR) probes and ARMS technology-based technique using the Ipsogen JAK2 RGQ PCR Kit.
resultsThe JAK2 V617F mutation was detected in 130 of 394 patients (32.9%). Subtype-specific JAK2 V617F detection rates were 48.1% for essential thrombocythemia (ET), 24.5% for polycythemia vera (PV), 22.2% for primary myelofibrosis (PMF) and 42.8% for Unspecified MPN patients. JAK2 V617F-positive PV and ET subtypes had a significantly higher mean age than JAK2 V617F-negative patients (p = 0.0002 and p = 0.029, respectively). The platelet (Plt) counts of JAK2 V617F-positive PV, Unspecified MPN and All groups were significantly higher than those in JAK2 V617F-negative patients (p < 0.0001, p = 0.0006 and p < 0.0001, respectively). The PMF subgroup had the highest mean JAK2 V617F allele burden (52.43 ± 34.74) compared with Unspecified MPN (51.81 ± 25.63), PV (47.38 ± 28.78) and ET patients (21.12 ± 16.34) (p < 0.0001). According to JAK2 V617F allele burden subtypes, only PV patients showed a significant increase in the white blood cell (WBC) count and hematocrit (Hct) related to incremental increases in the V617F allele burden (p < 0.0001).
conclusionsThe allele burden of JAK2 V617F was significantly lower in ET than in PV and PMF. Only the WBC, Hct and Plt counts were significantly different among the JAK2 V617F allele burden subgroups. Measuring the JAK2 V617F allele burden quantitatively might be an additional tool for predicting the hematological outcomes of MPNs.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.